2022
Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)
Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.Peer-Reviewed Original ResearchConceptsT cell responsesAnti-spike IgGVisit 3SARS-CoV-2Older PWHVisit 2Immune responseSingle-center longitudinal observational studyVirus-specific T cell responsesVaccine-induced humoral immunityLong-term protective immunityT cell immune responsesOlder peopleMedian age 61RBD IgG levelsPrimary study outcomeCOVID-19 vaccinationImmune response evaluationLongitudinal observational studyCOVID-19 vaccineWilcoxon signed-rank testBNT162b2 boosterBNT162b2 vaccinationCD8 responsesDetectable CD4Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 spike interaction with hACE2
Ssenyange G, Kerfoot M, Zhao M, Farhadian S, Chen S, Peng L, Ren P, Dela Cruz CS, Gupta S, Sutton RE. Development of an efficient reproducible cell-cell transmission assay for rapid quantification of SARS-CoV-2 spike interaction with hACE2. Cell Reports Methods 2022, 2: 100252. PMID: 35757815, PMCID: PMC9213030, DOI: 10.1016/j.crmeth.2022.100252.Peer-Reviewed Original ResearchConceptsAnti-spike monoclonal antibodiesTransmission assaysTherapeutic antiviral drugsSARS-CoV-2Quantitative readoutVirus-cell bindingRapid quantificationConvalescent seraNeutralization assaysAntiviral drugsResearch reagentsSmall molecule drugsClinical settingViral replicationPseudotyped particlesMonoclonal antibodiesLaboratory equipmentQuantitative assay
2021
COVID-19 Outcomes and Genomic Characterization of SARS-CoV-2 Isolated From Veterans in New England States: Retrospective Analysis
Lee M, Sallah YH, Petrone M, Ringer M, Cosentino D, Vogels CBF, Fauver JR, Alpert TD, Grubaugh ND, Gupta S. COVID-19 Outcomes and Genomic Characterization of SARS-CoV-2 Isolated From Veterans in New England States: Retrospective Analysis. JMIRx Med 2021, 2: e31503. PMID: 35014989, PMCID: PMC8722526, DOI: 10.2196/31503.Peer-Reviewed Original ResearchSARS-CoV-2 infectionPeak disease severityCOVID-19 outcomesChart reviewMean ageDisease severityHigher comorbidity burdenRetrospective chart reviewSARS-CoV-2 RNACohort of veteransGeneral US populationNon-white raceCOVID-19 infectionManual chart reviewSARS-CoV-2Multivariate regression analysisO2 requirementsNon-white veteransSARS-CoV-2 lineagesComorbidity burdenVirologic factorsD614G substitutionMultiple SARS-CoV-2 lineagesVirologic characteristicsClinical outcomes
2020
SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent?
Federman DG, Gupta S, Stack G, Campbell SM, Peaper DR, Dembry LM, Fisher A, Tarabar AF, Kozal M, Ruser CB. SARS-CoV-2 detection in setting of viral swabs scarcity: Are MRSA swabs and viral swabs equivalent? PLOS ONE 2020, 15: e0237127. PMID: 32756602, PMCID: PMC7406068, DOI: 10.1371/journal.pone.0237127.Peer-Reviewed Original ResearchConceptsMRSA swabsViral swabSARS-CoV-2 PCR testingCopan ESwabSevere acute respiratory syndromeMRSA nasal swabSARS-CoV-2 assayAcute respiratory syndromeCOVID-19SARS-CoV-2SARS-CoV-2 detectionNasopharyngeal swabsCoronavirus 2Nasal swabsRespiratory syndromePCR testingSwab collectionSwabsSwab samplesCepheid Xpert XpressXpert XpressWidespread testingCollection kitHealthcare systemViral media